Loading
institutionsInstitution
Fred & Pamela Buffett Cancer Center
Nebraska's NCI-designated centre, a longstanding leader in lymphoma classification and transplant and in pancreatic cancer early detection research.
Also called: UNMC Eppley Cancer CenterNebraska Medicine cancer center
Overview
The Fred & Pamela Buffett Cancer Center, whose research and hospital tower opened in Omaha in 2017, is the NCI-designated centre of the University of Nebraska Medical Center and Nebraska Medicine, descended from the Eppley Institute (1961). James Armitage and the Nebraska Lymphoma Study Group shaped lymphoma classification and pioneered autologous transplant for lymphoma, a tradition continued by Julie Vose. The pancreatic cancer programme under Michael Hollingsworth holds an NCI SPORE and coordinates early-detection consortia on mucins and biomarkers. Rural outreach across the Great Plains is a defining feature of its catchment.
Location
Omaha, NE, US
Type
cancer center · University of Nebraska Medical Center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
clinical
OnCo score
#225 · 26 points (0 Newsweek + 8 NCI + 18 from 9 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Fred and Pamela Buffett Cancer Center, including child institutions. 37 works · 4,159 citations · 43% open access · 8% clinical trials · 0% reviews.
Oncology works per year
92022
122023
112024
02025
52026
Most works
- Krishtee Napit8 works
- Lady Beverly Luma8 works
- Danae Dinkel8 works
- Kendra L. Ratnapradipa8 works
- Shinobu Watanabe‐Galloway8 works
- Laura Schabloske7 works
- Rashmi Kumar5 works
- Tamara B. Robinson5 works
- Nicole R. McMillian4 works
- Keyonna M. King4 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2022.0051 | Journal of the National Comprehensive Cancer Network | 2022 | 860 |
| Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2024.0035 | Journal of the National Comprehensive Cancer Network | 2024 | 636 |
| NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 10.6004/jnccn.2023.0031 · open access | Journal of the National Comprehensive Cancer Network | 2023 | 458 |
| Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2022.0020 | Journal of the National Comprehensive Cancer Network | 2022 | 428 |
| Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2024.0029 | Journal of the National Comprehensive Cancer Network | 2024 | 352 |
| NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024 10.6004/jnccn.2024.0041 | Journal of the National Comprehensive Cancer Network | 2024 | 261 |
| NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 10.6004/jnccn.2024.0036 | Journal of the National Comprehensive Cancer Network | 2024 | 149 |
| NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023 10.6004/jnccn.2023.0046 · open access | Journal of the National Comprehensive Cancer Network | 2023 | 140 |
| NCCN Guidelines® Insights: Distress Management, Version 2.2023 10.6004/jnccn.2023.0026 · open access | Journal of the National Comprehensive Cancer Network | 2023 | 137 |
| NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 10.6004/jnccn.2024.0057 | Journal of the National Comprehensive Cancer Network | 2024 | 129 |
| NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023 10.6004/jnccn.2023.0057 · open access | Journal of the National Comprehensive Cancer Network | 2023 | 123 |
| Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2023.0034 · open access | Journal of the National Comprehensive Cancer Network | 2023 | 89 |
| Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology 10.6004/jnccn.2024.0056 | Journal of the National Comprehensive Cancer Network | 2024 | 81 |
| NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024 10.6004/jnccn.2024.0002 · open access | Journal of the National Comprehensive Cancer Network | 2024 | 53 |
| NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024 10.6004/jnccn.2024.0047 | Journal of the National Comprehensive Cancer Network | 2024 | 52 |
- Lymphoma
- Pancreatic cancer SPORE and early detection
- Transplant
Similar pages
- InstitutionMasonic Cancer Center, University of Minnesota
Shares NCI-Designated Cancer Centers, Allogeneic stem cell transplantation, National Cancer Institute (NIH).
- InstitutionO'Neal Comprehensive Cancer Center at UAB
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Allogeneic stem cell transplantation, National Cancer Institute (NIH).
- InstitutionSalk Institute Cancer Center
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionHolden Comprehensive Cancer Center, University of Iowa
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionMayo Clinic Comprehensive Cancer Center in Arizona
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionUC Davis Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH).
- InstitutionVCU Massey Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH).